吉列替尼联合VAA方案治疗FLT3-ITD突变的难治性急性髓系白血病1例并文献复习  

Gilteritinib combined with VAA regimen in the treatment of refractory acute myeloid leukemia with FLT3-ITD mutation and literature review

作　　者：李可昕 盘婉盈 吴少杰[1] 黄宇贤[1] LI Kexin;PAN Wanying;WU Shaojie

机构地区：[1]南方医科大学珠江医院,广州510280

出　　处：《临床血液学杂志》2021年第3期202-204,共3页Journal of Clinical Hematology

基　　金：国家自然科学基金资助项目(No:81302372)。

摘　　要：急性髓系白血病(acute myeloid leukemia,AML)是一种造血组织的恶性克隆性疾病,其特征是骨髓中异常的原始细胞累积,而正常的血细胞生成障碍。其中伴有人FMS样酪氨酸激酶3突变(human FMS-like tyrosine kinase 3 mutant,FLT3mut+)的AML是业界公认的难治性白血病,常规化疗缓解率仅30%,耐药率及复发率极高,是现今AML治疗面临的大难题[1-2]。The clinical and laboratory characteristics of a patient with refractory acute myeloid leukemia combined with FLT3-ITD positive were reported. The patient received gilteritinib combination therapy. After treated with the combination of gilteritinib and VAA(venetoclax plus azacitidine and low-dose cytarabine) regimen, the patient achieved complete remission and obtained the time to complete the hematopoietic stem cell transplant. No serious adverse events were observed during oral gilteritinb or venetoclax, suggesting that gilteritinb combined with VAA regimen is safe and effective in the treatment of refractory acute myeloid leukemia with FLT3-ITD mutation.

关 键 词：FLT3-ITD突变 FLT3抑制剂 难治性急性髓系白血病 维克特拉 吉列替尼 

分 类 号：R733.71[医药卫生—肿瘤]